Dalcetrapib is under clinical development by DalCor Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

blackjack no deposit sign up bonus Drug clinical trial quality management regulations announced and implemented on July 1 Amgen's Repatha approved for the treatment of primary hypercholesterolemia and ...

Exercise: Aim for 150 minutes of moderate aerobic activity per week, like brisk walking or cycling. Stress Reduction: ...

Blood Sugar Control: Keeping HbA1c levels below 7 per cent minimizes vascular damage and reduces the risk of complications.

INR:3883. cbfs t20 league live score Amgen's Repatha approved for the treatment of primary hypercholesterolemia and mixed dyslipidemia 『Pharmaceutica ...

The FDA approved olezarsen (Tryngolza) as the first drug for adults with familial chylomicronemia syndrome, a rare genetic ...

The global cardiometabolic drugs market is projected to grow from US$ 50 billion in 2021 to over US$ 70 billion by 2032, with a CAGR of 4% to 5%. Sales are expected to surpass US$ 55 billion by 2022, ...

Lim Soo, a professor of endocrine metabolism at Seoul National University Bundang Hospital (a professor of internal medicine ...

New research suggests that activation of the PPARδ protein, which is linked to inflammation, could treat or prevent diabetic cardiomyopathy, a serious heart condition.

NEW ORLEANS -- Patients at a community health center who had type 2 diabetes and a high risk of atherosclerotic ...

Zodasiran is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase II program in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).

The participants had overweight or obesity and had at least one comorbidity, such as hypertension, dyslipidemia, obstructive ...